Immunotherapeutic approaches to hepatocellular carcinoma treatment
about
Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advancesTranscatheter embolization therapy in liver cancer: an update of clinical evidencesDCVax®-L--developed by Northwest BiotherapeuticsImmunotherapeutic approaches for hepatocellular carcinomaRole of antiviral therapy in reducing recurrence and improving survival in hepatitis B virus-associated hepatocellular carcinoma following curative resection (Review)Treatment for hepatocellular carcinoma in Japan over the last three decades: Our experience and published work reviewImmunotherapy for hepatocellular carcinoma: From basic research to clinical use.Development of inCVAX, In situ Cancer Vaccine, and Its Immune Response in Mice with Hepatocellular Cancer.Annonaceous acetogenins reverses drug resistance of human hepatocellular carcinoma BEL-7402/5-FU and HepG2/ADM cell linesMetastatic colorectal cancer in a cirrhotic liver with synchronous hepatocellular carcinoma.Radiofrequency ablation-combined multimodel therapies for hepatocellular carcinoma: Current status.Immune-based Therapy Clinical Trials in Hepatocellular CarcinomaSegmental Transarterial Embolization in a Translational Rat Model of Hepatocellular Carcinoma.Clinical implications of basic research in hepatocellular carcinoma.Fighting Viral Infections and Virus-Driven Tumors with Cytotoxic CD4+ T Cells.ISG15 in the tumorigenesis and treatment of cancer: An emerging role in malignancies of the digestive system.MICA SNPs and the NKG2D system in virus-induced HCC.The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following?Lentivirus mediated silencing of ubiquitin specific peptidase 39 inhibits cell proliferation of human hepatocellular carcinoma cells in vitro.Cellular and molecular targets for the immunotherapy of hepatocellular carcinoma.Serum Cytokeratin 18 M30 Levels in Chronic Hepatitis B Reflect Both Phase and Histological Activities of Disease.Rethinking cancer immunotherapy: Using advanced cancer genetics in immune-mediated eradication of gastrointestinal cancers.miR-370 regulates ISG15 expression and influences IFN-α sensitivity in hepatocellular carcinoma cells.
P2860
Q26745338-135E99F4-F4BA-4319-8ACB-D2A9E7435CD4Q27003849-7280F201-23A3-47B7-A80E-36D54F78AD31Q30875456-B425A521-00AE-4BAF-9359-21E2DA404E92Q33779723-73A449E5-25A8-4ACB-BB4D-F9EEBF693CA7Q34993924-D3F17CB6-8DA1-4E9D-88F7-BCEACE0656EBQ35037545-1797E1AE-3292-48EE-80F4-3E83D8FC2FB3Q35567765-6B901CFD-5F44-433A-87C4-95CB58FC27CBQ36140389-573C1E14-C235-47A4-96C0-7E0D5683CD51Q36262159-FFE09D97-1FC5-4DA3-9982-E33A7B24C517Q36345826-8920D09F-86EF-4E07-95CB-3373E3162134Q36390438-2B5FDD27-5F42-4A8C-9F1F-AE4A48A58A1BQ36571270-E3C7601A-E137-4F2A-8004-322079160FCEQ36857866-EE4CDA2D-F7CC-4269-B10C-FF7BCF591532Q37289933-81F3E1A9-F344-4ACB-8200-A941049594ACQ37667998-1D7DC0DC-94A4-4095-BCDC-93F95784CDB4Q37687572-6C7DBE3A-737C-42E1-A1EB-B0A547C2C5D1Q38255751-89B77EC6-A53F-47CA-9952-15FA612CA663Q38835601-D94F9795-D26E-4A7A-A8F2-E2918B2C26DBQ38885249-75CF9AA2-C784-4244-BC7B-DC3B2B6D29A3Q39358916-CFB6B799-7CC2-4B4E-A35D-6ED0CE126A83Q40084913-248FEC00-E139-463A-A79D-D19E06C8C65EQ54462341-5AB58DC9-C1FD-47F9-A331-4748F6CF07E6Q55415024-C9288DFB-59E6-4D61-AF83-238E141D137B
P2860
Immunotherapeutic approaches to hepatocellular carcinoma treatment
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Immunotherapeutic approaches to hepatocellular carcinoma treatment
@en
Immunotherapeutic approaches to hepatocellular carcinoma treatment.
@nl
type
label
Immunotherapeutic approaches to hepatocellular carcinoma treatment
@en
Immunotherapeutic approaches to hepatocellular carcinoma treatment.
@nl
prefLabel
Immunotherapeutic approaches to hepatocellular carcinoma treatment
@en
Immunotherapeutic approaches to hepatocellular carcinoma treatment.
@nl
P2860
P356
P1433
P1476
Immunotherapeutic approaches to hepatocellular carcinoma treatment
@en
P2093
Alexander G Miamen
Haidong Dong
P2860
P304
P356
10.1159/000343837
P577
2012-11-01T00:00:00Z